PD-1 resistant head and neck cancer- PPT
                     PD-1 Resistant Head and Neck 
Cancer
Presented by- DelveInsight Business Research

What is PD-1 resistant head and 
neck cancer?
Radiation therapy is the use of high-energy x-rays or other particles to destroy cancer cells. A 
radiation therapy regimen, or schedule, usually consists of a specific number of treatments given 
over a set period of time. It can be the main treatment for Metastatic Head and Neck Cancer, or it 
can be used after surgery to destroy small areas of cancer that cannot be removed surgically
Each of these types of therapies is discussed subsequently in more detail. A person may 
receive 1 type of systemic therapy at a time or a combination of systemic therapies 
given at the same time. They can also be given as part of a treatment plan that includes 
surgery and/or radiation therapy.
The medications used to treat cancer are continually being evaluated. Talking with the doctor is often 
the best way to learn about the medications prescriptions, their purpose, and their potential side 
effects or interactions with other medications. It is also important to let the doctor know if the patient 
is taking any other prescription or over-the-counter medications or supplements. Herbs, supplements, 
and other drugs can interact with cancer medications.
Also, Read @ PD-1 resistant head and neck cancer Market Research
How Many Regions Are 
Covered?
● The US
● EU5 (Germany, France, Italy, Spain, 
and the United Kingdom)
● Japan
What is PD-1 
Resistant Head 
and Neck 
Cancer?
This segment of the report provides a brief 
competitive analysis of PD-1 resistant 
head and neck cancer, to help 
understand the competition in the market. It 
gives a comparative understanding of the 
products based on types of wounds.
      The treatment of recurrent disease is an extremely difficult and nuanced situation for 
the head and neck patient. Local/regional recurrence is likely best treated with 
surgery. The application of repeat courses of chemoradiation afterward have to be 
considered carefully. Repeat courses of chemoradiation as a definitive treatment can 
be effective in a minority of patients, but are usually mostly palliative.
       In the patient not eligible for surgery, clinical trial enrolment is encouraged. Although 
systemic therapy for local/regional recurrence or distant spread were associated with 
poor survival for decades, recent improvements including immunotherapy are 
changing the landscape and allowing for more multimodality management, including 
the aggressive treatment of oligometastatic, oligorecurrent and oligopersistent 
disease.
In the patient not eligible for surgery, clinical trial enrolment is encouraged. Although 
systemic therapy for local/regional recurrence or distant spread were associated with 
poor survival for decades, recent improvements including immunotherapy are 
changing the landscape and allowing for more multimodality management, including 
the aggressive treatment of oligometastatic, oligorecurrent and oligopersistent 
disease.
       The dynamics of the PD-1 resistant HNC cancer market may change in the coming 
years owing to the improvement in the rise in the number of healthcare spending 
across the world. Key players, such as Merck, Nanobiotix and others, are involved in 
developing the therapy for PD-1 resistant HNC.
       Original Source:- PD-1 resistant head and neck cancer Market Research Report
What is the PD-1 resistant head and 
neck cancer Report Scope?
● The report covers the descriptive overview of PD-1 Resistant Head and Neck Cancer (HNC), 
explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available 
therapies
● Comprehensive insight has been provided into the PD-1 Resistant Head and Neck Cancer (HNC) 
epidemiology and treatment in the 7MM
● Additionally, an all-inclusive account of both the current and emerging therapies for PD-1 
Resistant Head and Neck Cancer (HNC) are provided, along with the assessment of new 
therapies, which will have an impact on the current treatment landscape
● A detailed review of PD-1 Resistant Head and Neck Cancer (HNC) market; historical and 
forecasted is included in the report, covering drug outreach in the 7MM
● The report provides an edge while developing business strategies, by understanding trends 
shaping and driving the global PD-1 Resistant Head and Neck Cancer (HNC) market
What are the PD-1 resistant head 
and neck cancer Report Highlights?
● In the coming years, PD-1 Resistant Head and Neck Cancer (HNC) market is set to change due to 
the rising awareness of the disease, and incremental healthcare spending across the world; 
which would expand the size of the market to enable the drug manufacturers to penetrate more 
into the market
● The companies and academics are working to assess challenges and seek opportunities that 
could influence PD-1 Resistant Head and Neck Cancer (HNC) R&D. The therapies under 
development are focused on novel approaches to treat/improve the disease condition      
● Major players are involved in developing therapies for PD-1 Resistant Head and Neck Cancer 
(HNC). Launch of emerging therapies will significantly impact the PD-1 Resistant Head and Neck 
Cancer (HNC) market
● A better understanding of disease pathogenesis will also contribute to the development of novel 
therapeutics for PD-1 Resistant Head and Neck Cancer (HNC)
[email protected]
[email protected]
+91-9650213330
CREDITS: This presentation template was 
created by Slidesgo, including icons by 
DFola tYiconu,  aHnda invfoeg rAapnhiycs  Q& uimeagsetsi obyn  or 
Freepik
Query?
Please keep this slide for attribution
Than
CREDITS: This presentation template was 
created by Slidesgo, including icons by 
Flaticon, and infographics & images by 
kFresepik !